// App-Quantinova.ai

BSH19‐OR‐019 : Maintenance Therapy with the Oral Proteasome Inhibitor Ixazomib Significantly Prolongs Progression‐Free Survival Post‐Autologous Stem Cell Transplantation Vs Placebo in Patients with Newly Diagnosed Multiple Myeloma: Phase 3 TOURMALINE‐MM3 Trial

Researchers

Presenter

  • M. Kaiser

Principal Investigators

  • F. Gay

  • F.H. Schjesvold

  • M. Beksac

  • R. Hjek

  • K.C. Weisel

  • H. Goldschmidt

  • V. Maisnar

  • P. Moreau

  • C.-K. Min

  • A. Pluta

  • W.J. Chng

  • S. Zweegman

  • M.-V. Mateos

  • A. Spencer

  • S. Iida

  • G.J. Morgan

  • K. Suryanarayan

  • Z. Teng

  • T. Skacel

  • A. Palumbo

  • A.B. Dash

  • N. Gupta

  • R. Labotka

  • S.V. Rajkumar

Medical Centers

  • Department of Virology, Royal Free Hospital, London, United Kingdom

  • Hematology & Medical Oncology, Department of Clinical Therapeutics,National and Kapodistrian University of Athens, School of Medicine,Athens,Greece

  • Department of Oncology and Hematology,Azienda Ospedaliero-Universitaria City of Health and Science of Turin,Turin,Italy

  • Oslo Myeloma Center, Oslo University Hospital, Oslo Norway

  • Department of Rheumatology, Baskent University, Ankara, Turkey

  • Department of Neurosurgery, University Hospital Ostrava, Ostrava, Czech Republic

  • Dept. Internal Medicine II, University Hospital, Tuebingen, Germany

  • Department of Neurology, University Hospital Heidelberg and National Center of Tumor Diseases, Heidelberg, Germany

  • Fourth Department of Medicine ‐ Hematology, University Hospital Hradec Králové, Hradec Králové, Czech Republic

  • Hematology Biology, University Hospital Hotel Dieu, Nantes, France

  • Department of Internal Medicine, St. Paul's Hospital, Seoul, Korea, Republic of,

  • Department of Hematology, Medical University of Lodz, Multidisciplinary Provincial Centre of Traumatology and Oncology Nicolas Copernicus in Lodz, Lodz, Poland

  • Department of Haematology-Oncology, National University Cancer Institute, National University Health System, Singapore, Singapore

  • Department of Hematology,Amsterdam University Medical Center, University of Amsterrdam, Cancer Center Amsterdam and LYMMCARE,Amsterdam,Niederlande

  • Department of Hematology, University Hospital of Salamanca, Salamanca, Spain

  • Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, Australia

  • Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

  • Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR

  • Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Deerfield, IL

  • Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero‐Universitaria S Giovanni Battista, Turin, Italy

  • Division of Hematopathology, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN

Locations

  • United Kingdom

  • Greece

  • Italy

  • Norway

  • Turkey

  • Czech Republic

  • Germany

  • France

  • Poland

  • Singapore

  • Netherlands

  • Spain

  • Australia

  • Japan

  • United States

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

  • Peripheral Nervous System

  • Blood/haematological Diseases

  • Oncology (ONC)

Disease

  • Gastrointestinal syndrome

  • Peripheral neuropathy

  • Multiple Myeloma

  • Neutropenia

Biomarkers

  • N/A

Drug/Treatment

  • Lenalidomide

  • Thalidomide

  • Bortezomib

  • Hydroxyzine

  • Ixazomib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multinational

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT02181413

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved